These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 34462337)

  • 1. Residual homing of α4β7-expressing β1
    Becker E; Dedden M; Gall C; Wiendl M; Ekici AB; Schulz-Kuhnt A; Schweda A; Voskens C; Hegazy A; Vitali F; Atreya R; Müller TM; Atreya I; Neurath MF; Zundler S
    Gut; 2022 Aug; 71(8):1551-1566. PubMed ID: 34462337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Etrolizumab-s Does Not Induce Residual Trafficking of Regulatory T Cells.
    Schweda A; Becker E; Wiendl M; Atreya R; Atreya I; Müller TM; Neurath MF; Zundler S
    Inflamm Bowel Dis; 2022 Nov; 28(11):1746-1755. PubMed ID: 35815779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential effects of α4β7 and GPR15 on homing of effector and regulatory T cells from patients with UC to the inflamed gut in vivo.
    Fischer A; Zundler S; Atreya R; Rath T; Voskens C; Hirschmann S; López-Posadas R; Watson A; Becker C; Schuler G; Neufert C; Atreya I; Neurath MF
    Gut; 2016 Oct; 65(10):1642-64. PubMed ID: 26209553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Vedolizumab Level, Anti-Drug Antibodies, and α4β7 Occupancy With Response in Patients With Inflammatory Bowel Diseases.
    Ungar B; Kopylov U; Yavzori M; Fudim E; Picard O; Lahat A; Coscas D; Waterman M; Haj-Natour O; Orbach-Zingboim N; Mao R; Chen M; Chowers Y; Eliakim R; Ben-Horin S
    Clin Gastroenterol Hepatol; 2018 May; 16(5):697-705.e7. PubMed ID: 29223444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blockade of αEβ7 integrin suppresses accumulation of CD8
    Zundler S; Schillinger D; Fischer A; Atreya R; López-Posadas R; Watson A; Neufert C; Atreya I; Neurath MF
    Gut; 2017 Nov; 66(11):1936-1948. PubMed ID: 27543429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vedolizumab blocks α4β7 integrin-mediated T cell adhesion to MAdCAM-1 in microscopic colitis.
    Besendorf L; Müller TM; Geppert CI; Schneider I; Mühl L; Atreya I; Vitali F; Atreya R; Neurath MF; Zundler S
    Therap Adv Gastroenterol; 2022; 15():17562848221098899. PubMed ID: 35784193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vitamin D Is Associated with α4β7+ Immunophenotypes and Predicts Vedolizumab Therapy Failure in Patients with Inflammatory Bowel Disease.
    Gubatan J; Rubin SJS; Bai L; Haileselassie Y; Levitte S; Balabanis T; Patel A; Sharma A; Sinha SR; Habtezion A
    J Crohns Colitis; 2021 Dec; 15(12):1980-1990. PubMed ID: 34180967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-classical monocyte homing to the gut via α4β7 integrin mediates macrophage-dependent intestinal wound healing.
    Schleier L; Wiendl M; Heidbreder K; Binder MT; Atreya R; Rath T; Becker E; Schulz-Kuhnt A; Stahl A; Schulze LL; Ullrich K; Merz SF; Bornemann L; Gunzer M; Watson AJM; Neufert C; Atreya I; Neurath MF; Zundler S
    Gut; 2020 Feb; 69(2):252-263. PubMed ID: 31092589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases.
    Soler D; Chapman T; Yang LL; Wyant T; Egan R; Fedyk ER
    J Pharmacol Exp Ther; 2009 Sep; 330(3):864-75. PubMed ID: 19509315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease.
    Zeissig S; Rosati E; Dowds CM; Aden K; Bethge J; Schulte B; Pan WH; Mishra N; Zuhayra M; Marx M; Paulsen M; Strigli A; Conrad C; Schuldt D; Sinha A; Ebsen H; Kornell SC; Nikolaus S; Arlt A; Kabelitz D; Ellrichmann M; Lützen U; Rosenstiel PC; Franke A; Schreiber S
    Gut; 2019 Jan; 68(1):25-39. PubMed ID: 29730603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating exosomes express α4β7 integrin and compete with CD4+ T cells for the binding to Vedolizumab.
    Domenis R; Marino M; Cifù A; Scardino G; Curcio F; Fabris M
    PLoS One; 2020; 15(11):e0242342. PubMed ID: 33180848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The α4β1 Homing Pathway Is Essential for Ileal Homing of Crohn's Disease Effector T Cells In Vivo.
    Zundler S; Fischer A; Schillinger D; Binder MT; Atreya R; Rath T; Lopez-Pósadas R; Voskens CJ; Watson A; Atreya I; Neufert C; Neurath MF
    Inflamm Bowel Dis; 2017 Mar; 23(3):379-391. PubMed ID: 28221249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases.
    Lynch KD; Chapman RW; Keshav S; Montano-Loza AJ; Mason AL; Kremer AE; Vetter M; de Krijger M; Ponsioen CY; Trivedi P; Hirschfield G; Schramm C; Liu CH; Bowlus CL; Estes DJ; Pratt D; Hedin C; Bergquist A; de Vries AC; van der Woude CJ; Yu L; Assis DN; Boyer J; Ytting H; Hallibasic E; Trauner M; Marschall HU; Daretti LM; Marzioni M; Yimam KK; Perin N; Floreani A; Beretta-Piccoli BT; Rogers JK; ; Levy C
    Clin Gastroenterol Hepatol; 2020 Jan; 18(1):179-187.e6. PubMed ID: 31100458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blocking GPR15 Counteracts Integrin-dependent T Cell Gut Homing in Vivo.
    Schramm S; Liu LJ; Saad M; Dietz L; Dedden M; Müller TM; Atreya I; Voskens CJ; Atreya R; Neurath MF; Zundler S
    J Crohns Colitis; 2024 Aug; 18(7):1162-1172. PubMed ID: 38243565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vedolizumab Efficacy Is Associated With Decreased Intracolonic Dendritic Cells, Not Memory T Cells.
    Boden EK; Kongala R; Hindmarch DC; Shows DM; Juarez JG; Lord JD
    Inflamm Bowel Dis; 2024 May; 30(5):704-717. PubMed ID: 37837660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of Candidate Biomarkers Associated with Response to Vedolizumab in Inflammatory Bowel Disease.
    Boden EK; Shows DM; Chiorean MV; Lord JD
    Dig Dis Sci; 2018 Sep; 63(9):2419-2429. PubMed ID: 29372476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Limited Dose-Dependent Effects of Vedolizumab on Various Leukocyte Subsets.
    Becker E; Schweda A; Ullrich KA; Voskens C; Atreya R; Müller TM; Atreya I; Neurath MF; Zundler S
    Clin Transl Gastroenterol; 2022 Jun; 13(6):e00494. PubMed ID: 35575178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dissecting Common and Unique Effects of Anti-α4β7 and Anti-Tumor Necrosis Factor Treatment in Ulcerative Colitis.
    Veny M; Garrido-Trigo A; Corraliza AM; Masamunt MC; Bassolas-Molina H; Esteller M; Arroyes M; Tristán E; Fernández-Clotet A; Ordás I; Ricart E; Esteve M; Panés J; Salas A
    J Crohns Colitis; 2021 Mar; 15(3):441-452. PubMed ID: 32926095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential Effects of Ontamalimab Versus Vedolizumab on Immune Cell Trafficking in Intestinal Inflammation and Inflammatory Bowel Disease.
    Schulze LL; Becker E; Dedden M; Liu LJ; van Passen C; Mohamed-Abdou M; Müller TM; Wiendl M; Ullrich KAM; Atreya I; Leppkes M; Ekici AB; Kirchner P; Stürzl M; Sexton D; Palliser D; Atreya R; Siegmund B; ; Neurath MF; Zundler S
    J Crohns Colitis; 2023 Nov; 17(11):1817-1832. PubMed ID: 37208197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression and function of α4β7 integrin predict the success of vedolizumab treatment in inflammatory bowel disease.
    Schneider I; Allner C; Mühl L; Melde M; Lissner D; Mantzivi E; Glauben R; Vitali F; Becker E; Atreya I; Müller TM; Atreya R; Siegmund B; Neurath MF; Zundler S
    Transl Res; 2023 Mar; 253():8-15. PubMed ID: 36272713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.